<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Exendin-4 is a dipeptidyl peptidase IV (DPP-IV)-resistant glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) mimetic and its synthetic counterpart, exenatide, is being used in the therapy of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>No information, however, is currently available as for the direct action of exendin-4 on human T2DM islets </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we exposed pancreatic islets prepared from non-diabetic and T2DM subjects to exendin-4 for 48 h and found that the compound had several, direct beneficial actions on insulin secretion and the expression of genes involved in beta-cell function and differentiation </plain></SENT>
</text></document>